PeptideTreatments
Reviewed by Peptide Treatments Medical Advisory Board

VIP: Research & Evidence

Emerging Evidence

Published research, clinical trial data, and evidence grading for VIP across studied indications.

Back to VIP overview

Research Summary

VIP is a 28-amino acid neuropeptide with broad physiological effects including immunomodulation, neuroprotection, and anti-inflammatory activities. Research demonstrates promising results in neurodegenerative diseases, inflammatory bowel disease, and respiratory conditions through VPAC1/VPAC2 receptor signaling.

Evidence by Indication (3 indications)

Indication Tier Trials Summary
Pulmonary hypertension Tier C 2 Inhaled VIP reduces pulmonary artery pressure in small trials
GI motility disorders Tier C 2 Regulates intestinal motility and secretion; clinical applications in functional GI disorders
Neuroprotection Tier D 1 Anti-inflammatory effects in neuroinflammation models; human data limited

Graded using our evidence tier methodology.

Research Gap Score /10

Higher score = larger gap between therapeutic potential and available clinical evidence.

Citations (7 sources)

  1. 1. Overexpression of colonic VIP ameliorates cognitive function and barrier system damage caused by sevoflurane anesthesia and surgery in aged rats with fragile brain functions. Study

    Liao H, Wang X, Yang C, Wang Z, Liu X, et al. (2025), Experimental neurology

  2. 2. Increased Expression of the Neuropeptides PACAP/VIP in the Brain of Mice with CNS Targeted Production of IL-6 Is Mediated in Part by Trans-Signalling. Study

    Castorina A, Scheller J, Keay KA, Marzagalli R, Rose-John S, et al. (2024), International journal of molecular sciences

  3. 3. Differential Expression of PACAP/VIP Receptors in the Post-Mortem CNS White Matter of Multiple Sclerosis Donors. Study

    Jansen MI, Musumeci G, Castorina A (2024), International journal of molecular sciences

  4. 4. Targeting the PAC1 receptor mitigates degradation of myelin and synaptic markers and diminishes locomotor deficits in the cuprizone demyelination model. Study

    Jansen MI, Mahmood Y, Lee J, Broome ST, Waschek JA, et al. (2024), Journal of neurochemistry

  5. 5. Extracellular vesicles from primary human macrophages stimulated with VIP or PACAP mediate anti-SARS-CoV-2 activities in monocytes through NF-kB signaling pathway. Study

    Arteaga-Blanco LA, Temerozo JR, Tiné LPS, Dantas-Pereira L, Sacramento CQ, et al. (2024), Microbes and infection

  6. 6. The impact of exogenous vasoactive intestinal polypeptide on inflammatory responses and mRNA expression of tight junction genes in lambs fed a high-grain diet. Study

    Mia GK, Hawley E, Yusuf M, Amat S, Ward AK, et al. (2024), Journal of animal science

  7. 7. VIP in ulcerative colitis RCT. Clinical Trial

    (2005)